TITLE

Cardiovascular Effects of Pharmacologic Treatments for Obesity

AUTHOR(S)
Aronne, Louis J.
PUB. DATE
January 1998
SOURCE
Nutrition in Clinical Care;Jan/Feb98 Supplement 1, Vol. 1 Issue 1, p51
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Examines the cardiovascular effects of pharmacologic treatment for obesity in the United States. Complications of obesity; Development of sibutramine as an antidepressant; Association between sibutramine and heart disease and hypertension.
ACCESSION #
5892378

 

Related Articles

  • SIZE MATTERS. GREENHALGH, TRISHA // Accountancy;Dec2010, Vol. 146 Issue 1408, p55 

    The author emphasizes the benefit of gastric surgery to severely obese people. She cites some of the diseases related to obesity including diabetes, heart disease and arthritis. She notes the withdrawal of anti-obesity drugs ribonamant and sibutramine from the market due to life-threatening side...

  • A Randomized Trial of Sibutramine in the Management of Obese Type 2 Diabetic patients Treated With Metformin. McNulty, Steven J.; Ur, Ehud; Williams, Gareth // Diabetes Care;Jan2003, Vol. 26 Issue 1, p125 

    OBJECTIVE To evaluate the effects of sibutramine (15 and 20 mg/day) on weight, metabolic control, and blood pressure in metformin-treated obese subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS — A 12-month randomized prospective placebo-controlled double-blind study was...

  • Continuous and intermittent sibutramine were equally effective at 44 weeks for reducing weight in obese persons. Cheskin, Lawrence J. // ACP Journal Club;Mar/Apr2002, Vol. 136 Issue 2, p49 

    Presents information on a study which examined the effectiveness of sibutramine for reducing weight in obese patients. Methodology of the study; Results; Comments on the study.

  • Sibutramine safety review.  // WHO Drug Information;2002, Vol. 16 Issue 1, p26 

    Reports on action taken by regulatory agencies of various countries regarding the prescription drug sibutramine. Approval of the drug in Canada in December 2000 to treat obesity; Italian authorities' temporary suspension of market authorization of all drugs containing sibutramine in March 2002;...

  • FDA requests withdraw of sibutramine from US market.  // Cardiology Today;Dec2010, Vol. 13 Issue 12, p24 

    The article reports that a recommendation against the continued prescription and use of sibutramine has been issued by the U.S. Food and Drug Administration (FDA) in line with the elevated cardiovascular (CV) risks observed in some patients taking the drug.

  • Pharmacological Treatment of Obesity: Current Standards and Future Perspectives. Romijn, J. A.; Smit, J. W. A.; Pereira, A. M.; Corssmit, E. P. M.; Pijl, H. // Immunology, Endocrine & Metabolic Agents - Medicinal Chemistry;Feb2006, Vol. 6 Issue 1, p119 

    The long-term effects on weight have only been studied for orlistat and sibutramine. The net effects of these drugs vary between 2-5% loss of weight after 1-2 years of treatment. However, the effects of orlistat and sibutramine on morbidity and mortality have not been studied extensively. In the...

  • FROM THE ANALYST'S COUCH: Obesity market overview. Farrigan, Christine; Pang, Kevin // Nature Reviews Drug Discovery;Apr2002, Vol. 1 Issue 4, p257 

    Presents an overview of available pharmacological therapies for obesity. Sibutramine; Axokine; Bupropion; Recombinant human leptin; Topiramate; Forecast of sales of antiobesity agents by 2010.

  • A clinical trial of the use of Sibutramine for the treatment of patients suffering essential obesity. Fanghänel, G; Cortinas, L; Sánchez-Reyes, L; Berber, A // International Journal of Obesity & Related Metabolic Disorders;Feb2000, Vol. 24 Issue 2, p144 

    OBJECTIVE: To evaluate the safety and efficacy of Sibutramine 10 mg per os, once a day in obese patients over a period of 6 months. DESIGN: A monocenter, double-blind, placebo-controlled, parallel, prospective clinical trial. SUBJECTS: 109 male and female obese patients (BMI >30 kg/m²) from...

  • Sibutramine/zolpidem interaction.  // Reactions Weekly;Feb2014, Vol. 1488 Issue 1, p31 

    The article presents a case study of a 61-year old woman who suffered from two psychotic episodes during treatment with sibutramine for obesity.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics